TY - JOUR
T1 - Chemoprevention of pancreatic cancer
T2 - Ready for the clinic?
AU - Logsdon, Craig D.
AU - Abbruzzese, James L.
PY - 2010/11
Y1 - 2010/11
N2 - Advances in our molecular, clinical, and epidemiologic understanding of the risk and development of pancreatic cancer offer hope for preventing this disease, which is largely intractable once developed. This perspective on provocative, genetically engineered mouse model work reported by Mohammed et al. (beginning on page 1417 in this issue of the journal) examines the prospects for pancreatic cancer chemoprevention with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI). Despite having limited value in advanced pancreatic cancer, EGFR TKIs show promise in the setting of early pancreatic carcinogenesis.
AB - Advances in our molecular, clinical, and epidemiologic understanding of the risk and development of pancreatic cancer offer hope for preventing this disease, which is largely intractable once developed. This perspective on provocative, genetically engineered mouse model work reported by Mohammed et al. (beginning on page 1417 in this issue of the journal) examines the prospects for pancreatic cancer chemoprevention with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI). Despite having limited value in advanced pancreatic cancer, EGFR TKIs show promise in the setting of early pancreatic carcinogenesis.
UR - http://www.scopus.com/inward/record.url?scp=78649233246&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78649233246&partnerID=8YFLogxK
U2 - 10.1158/1940-6207.CAPR-10-0216
DO - 10.1158/1940-6207.CAPR-10-0216
M3 - Review article
C2 - 21084259
AN - SCOPUS:78649233246
SN - 1940-6207
VL - 3
SP - 1375
EP - 1378
JO - Cancer Prevention Research
JF - Cancer Prevention Research
IS - 11
ER -